segunda-feira, 16 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleNasdaq· July 29, 2026

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

View original at nasdaq.com
Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?…
Opening lines of the source · Nasdaq · short snapshot: read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Initial safety, tolerability, pharmacokinetic, and immune data for MDX2001 are expected in the first half of 2027.

    60% confidence
  • Kiniksa raised its full-year 2026 net product revenue guidance for Arcalyst to $980 million to $995 million.

    60% confidence
  • ProMIS expects to report topline 12-month results from the PRECISE-AD trial in the first quarter of 2027.

    60% confidence
  • OPKO expects full-year 2026 total revenue of $560 million to $580 million.

    60% confidence
  • Prelude expects an IND application submission for PRT13722 by mid-2026 and a Phase 1 study initiation in ER-positive breast cancer in the second half of 2026.

    60% confidence
  • Enrollment for the MDX2301 Phase 1 trial is expected to be completed in Q3 2026, with initial data anticipated in late 2026 or early 2027.

    60% confidence
  • OPKO forecasts Q3 2026 revenue of $131 million to $142 million.

    60% confidence
  • MapLight plans to engage the FDA at an End-of-Phase 2 meeting to discuss the path forward for ML-007C-MA in schizophrenia, including the design of a Phase 3 trial.

    60% confidence
  • The VISTA trial is designed to enroll approximately 300 participants, with topline results expected in the second half of 2027.

    60% confidence

Citado nestas reportagens da Via News